Allosterix Pharmaceuticals

Company Overview

Snapshot

Founded in July 2007 by Ariel Solomon and Omer Vunsch, Allosterix Pharmaceuticals operates with 1–10 employees. The company focuses on drug design and discovery, and in September 2010, it expanded its Scientific Advisory Board.

Business overview

Allosterix Pharmaceuticals is a health tech and life sciences company specializing in the development of highly selective peptide-based inhibitors. The company's core technology involves a patent-pending approach to drug design that identifies allosteric sites for peptidic drug development, aiming for greater specificity and reduced side effects. Allosterix Pharmaceuticals serves the pharmaceutical and biotechnology industries, particularly laboratories focused on drug discovery and development.

Company Intelligence Q&A

What is Allosterix Pharmaceuticals' primary focus?

Allosterix Pharmaceuticals focuses on developing highly selective peptide-based inhibitors by utilizing a patent-pending technology for locating allosteric sites and designing peptidic drugs.

When was Allosterix Pharmaceuticals founded?

Allosterix Pharmaceuticals was founded in July 2007.

Who are the founders of Allosterix Pharmaceuticals?

Allosterix Pharmaceuticals was co-founded by Ariel Solomon and Omer Vunsch.

What is the key advantage of Allosterix Pharmaceuticals' drug design approach?

The company's approach to drug design, based on allostery, offers greater specificity and inherent selectivity in each peptidic inhibitor, leading to a low incidence of unwanted side effects or toxicity.

What was a notable development for Allosterix Pharmaceuticals in September 2010?

In September 2010, Allosterix Pharmaceuticals expanded its Scientific Advisory Board to further its drug design and discovery efforts.